Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
American Well Corporation filings document the company’s SaaS-based technology-enabled healthcare platform, operating results, customer agreements, governance, and equity-compensation structure. Its Form 8-K filings include earnings reports for quarterly and annual periods, material definitive agreements, board changes, and related exhibit disclosures.
AMWL filings also describe commercial arrangements tied to digital care delivery, including the company’s operation of a white-labeled platform under the LiveHealth Online brand for Elevance Health and related clinical-provider access through Online Care Group. Proxy materials cover director elections, executive compensation, equity awards, stockholder voting matters, and board governance for the public company.
American Well Corporation reported first quarter 2026 results with shrinking losses but lower revenue year over year. Revenue was $54.9 million, down from $66.8 million a year earlier, with a gross margin of 51%.
Net loss was $10.3 million, improving from $18.4 million in first quarter 2025 and $25.2 million in fourth quarter 2025. Adjusted EBITDA was a loss of $3.1 million, better than a $12.2 million loss a year ago and $10.3 million in fourth quarter 2025. Total visits reached 1.1 million.
For full year 2026, Amwell reaffirmed revenue guidance of $195–$205 million, AMG visits of 1.32–1.37 million, and updated adjusted EBITDA guidance to a loss of $16–$12 million. For second quarter 2026, it expects revenue of $48–$52 million and adjusted EBITDA of a $4–$2 million loss, and continues to target positive cash flow from operations in the fourth quarter of 2026.
American Well Corporation (Amwell) is asking stockholders to vote at its 2026 virtual annual meeting on electing two Class III directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving executive pay on an advisory basis. The proxy also reviews 2025 performance, highlighting a shift to a tech‑enabled care platform and stronger operating discipline. Amwell recorded 2025 total revenue of $249.3 million, including $132.4 million of subscription revenue and $94.3 million of AMG visit revenue, with a 53% gross margin. Net loss narrowed to ($95.0) million from ($212.6) million in 2024, and total visits reached 4.5 million. Year‑end cash and short‑term securities were about $182.3 million. Management reiterates a goal of achieving positive operating cash flow in 2026 and emphasizes its Defense Health Agency SaaS deployment, AI‑enabled programs, and corporate responsibility initiatives. The Board remains majority‑independent and classified, and Amwell is a NYSE “controlled company” through Class B voting shares held by its co‑founders.
American Well Corp executive Phyllis Gotlib, President, International, reported an automatic sale of 3,706 shares of Class A Common Stock on April 1, 2026 at $5.30 per share. The sale was a non-discretionary “sell to cover” to pay taxes on vested restricted stock units.
After this transaction, Gotlib holds 163,004 shares directly and 114,250 shares indirectly through her husband, indicating the sale was small relative to her overall position and primarily for tax obligations rather than portfolio rebalancing.
American Well Corp Chief Product & Tech. Officer Dmitry Zamansky reported an open-market sale of 5,575 shares of Class A Common Stock at $5.30 per share. The footnote explains the sale was an automatic “sell to cover” to pay taxes from restricted stock units vesting on April 1, 2026, and not a discretionary trade. Following this transaction, he directly holds 241,080 shares.
American Well Corp Chief Accounting Officer Paul Francis McNeice reported a small, non-discretionary stock sale. On April 1, 2026, he sold 383 shares of Class A Common Stock at $5.30 per share to cover tax liabilities from vesting restricted stock units. After this sell-to-cover transaction, he directly holds 10,616 shares of American Well Corp.
American Well Corporation reports that board member Dr. Peter Slavin has notified the company he will resign from its Board of Directors, effective at the company’s next annual meeting of stockholders in 2026. He will continue to serve as a director until that meeting.
The company states that Dr. Slavin’s decision is due to his transition to a new role on the West Coast of the United States and is not the result of any disagreement regarding American Well’s operations, policies, or procedures. The company expresses appreciation for his more than nine years of board service.
American Well Corporation (AMWL) submitted a Form 144 notice reporting proposed transactions in Class A Common Stock tied to an RSU vesting event dated 04/01/2026. The filing lists share counts associated with the vesting and recent sales by Phyllis Gotlib on 01/02/2026 and 03/02/2026.
American Well Corporation filing a Form 144 shows 11,831 Class A common shares vested from a restricted stock unit grant on 04/01/2026 and discloses prior sales: 2,472 shares sold on 03/02/2026 for $14,090.40 and 6,243 shares sold on 01/02/2026 for $30,284.79.
HIRSCHHORN MARK reported acquisition or exercise transactions in this Form 4 filing.
American Well Corp reported that its Chief Financial Officer, Mark Hirschhorn, received an equity award tied to 50,413 shares of Class A common stock on March 4, 2026. The award was granted at no cash cost per share.
According to the footnote, this represents a grant of restricted stock units that will vest in equal quarterly installments over a two-year period, starting on the first calendar day of the month after three months from the grant date. Following this award, Hirschhorn directly holds 253,999 shares of Class A common stock.